Our top pick for
Recro Pharma Inc is a pharmaceuticals business based in the US. Recro Pharma shares (REPH) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$0.79|
|52-week range||$0.78 - $2.19|
|50-day moving average||$1.75|
|200-day moving average||$1.86|
|Wall St. target price||$5.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-17)||N/A|
|1 month (2022-08-24)||N/A|
|3 months (2022-06-24)||N/A|
|6 months (2022-03-24)||N/A|
|1 year (2021-09-28)||-61.84%|
|2 years (2020-09-28)||-63.43%|
|3 years (2019-09-27)||11.26|
|5 years (2017-09-28)||9.04|
Valuing Recro Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Recro Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Recro Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8 million.
The EBITDA is a measure of a Recro Pharma's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$75.4 million|
|Operating margin TTM||0.55%|
|Gross profit TTM||$19.8 million|
|Return on assets TTM||0.2%|
|Return on equity TTM||-81.32%|
|Market capitalisation||$123.2 million|
TTM: trailing 12 months
We're not expecting Recro Pharma to pay a dividend over the next 12 months.
Recro Pharma's shares were split on a 1115:1000 basis on 21 November 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1115 shares. This wouldn't directly have changed the overall worth of your Recro Pharma shares – just the quantity. However, indirectly, the new 10.3% lower share price could have impacted the market appetite for Recro Pharma shares which in turn could have impacted Recro Pharma's share price.
Over the last 12 months, Recro Pharma's shares have ranged in value from as little as $0.775 up to $2.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recro Pharma's is 1.1154. This would suggest that Recro Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Recro Pharma, Inc. , a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.